Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (see Methods and Evidence section below). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations. 

 

 

Download entire guideline in the most up-to-date version:

Download
3288

Last updated
Updated 2021
Download
Introduction, scoping, population and targeted users
10/2021
We welcome Ivan Bogdanov, Liam Mercieca and Dimitris Rigopoulos to the group.
Download
303
Disease severity and treatment goals
10/2021
No changes
Download
517
Methods and evidence section
12/2021
Editorial changes
Download
154
Main Recommendations and Decision Grid
10/2021
Bimekuzumab was added; guselkumab and PsA was added.
Download
598
Implementation slides
10/2021
Bimekuzumab was added; guselkumab and PsA was added
Download
285
IFPA Guideline
10/2021
No changes
Download
254

Last updated
Updated 2021
Download
Acitretin
10/2021
No changes
Download
184
Ciclosporin
10/2021
No changes
Download
132
Fumarates
10/2021
No changes
Download
85
Methotrexate
10/2021
No changes
Download
263
Adalimumab
10/2021
No changes
Download
119
Apremilast
10/2021
No changes
Download
144
Bimekizumab
10/2021
New chapter
Download
83
Brodalumab
10/2021
Section on IBD updated
Download
69
Certolizumab – Pegol
10/2021
No changes
Download
81
Etanercept
10/2021
No changes
Download
44
Guselkumab
10/2021
No changes
Download
96
Infliximab
10/2021
No changes
Download
50
Ixekizumab
10/2021
No changes
Download
86
Risankizumab
10/2021
No changes
Download
113
Secukinumab
10/2021
No changes
Download
89
Tildrakizumab
10/2021
No changes
Download
73
Ustekinumab
10/2021
No changes
Download
64
Biosimilars
10/2021
No changes
Download
59
Newly approved medications and treatments in the pipeline
10/2021
No changes
Download
134

Last updated
Updated 2021
Download
Psoriatic arthritis
10/2021
Recommendation concerning guselkumab added
Download
166
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Download
72
Cancer
10/2021
Editorial changes
Download
153
Depression
10/2021
No changes
Download
55
Diabetes Mellitus
10/2021
No changes
Download
107
Heart disease
10/2021
Recommendation concerning bimekizumab added (same as other IL 17)
Download
69
Kidney disease
10/2021
No changes
Download
39
Neurological diseases
10/2021
New data on ixekizumab added
Download
47
Viral Hepatitis
10/2021
No / update in progress
Download
127
Tuberculosis: Screening
10/2021
Editorial changes
Download
76
Tuberculosis: Treatment
10/2021
Editorial changes
Download
90
Wish for child / Pregnancy
10/2021
Time until pregnancy added for bimekizumab
Download
166
Vaccionations
10/2021
Information on bimekizumab added
Download
111
Vaccination against SARS-CoV-2
01/2022
Updated consensus statement
Download
197
Covid-19
10/2021
No changes
Download
213
Inmunogenicity
10/2021
No changes
Download
53

Last updated
Updated 2021
Download
Methods Report
10/2021
No changes
Download
127
Strength and limitations
10/2021
No changes
Download
54
References
10/2021
Added new references
Download
53
Abbreviations
10/2021
No changes
Download
21